Swiss National Bank
KALV

Swiss National Bank’s KalVista Pharmaceuticals KALV Stock Holding History

Swiss National Bank’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.11M Hold
54,900
– – ﹤0.01% 2117
2025
Q4 		$887K Buy
54,900
+6,400
+13% +$84.8K ﹤0.01% 2220
2025
Q3 		$591K Buy
+48,500
New +$670K ﹤0.01% 2281
2019
Q4 		– Sell
-17,600
Closed -$204K – 2521
2019
Q3 		$204K Hold
17,600
– – ﹤0.01% 2495
2019
Q2 		$390K Buy
+17,600
New +$413K ﹤0.01% 2474

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Swiss National Bank's KALV Position: Q1 2026 in Review

Swiss National Bank held its KalVista Pharmaceuticals (KALV) position steady in Q1 2026 at 54,900 shares worth $1.11M. The position accounts for ﹤0.01% of the portfolio, ranked #2117.

Swiss National Bank first reported a position in KALV in Q2 2019 and has held it in 5 quarters since. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • Swiss National Bank held 54,900 shares of KalVista Pharmaceuticals worth $1.11M as of Q1 2026.
  • Swiss National Bank left its KalVista Pharmaceuticals share count unchanged in Q1 2026.
  • KalVista Pharmaceuticals made up ﹤0.01% of Swiss National Bank's portfolio in Q1 2026, its #2117 holding.
  • Swiss National Bank first reported a position in KalVista Pharmaceuticals in Q2 2019 and has held it in 5 quarters since.
  • 183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Swiss National Bank's 13F filing for Q1 2026, filed 7 May 2026.